Benjamin M. Segal, M.D., joined the University of Michigan faculty in 2007. He directs the Multiple Sclerosis Center and the Holtom-Garrett Program in Neuroimmunology, which has a mission to provide and support excellent diagnostic and medical management services for patients with MS; cutting edge research in the pathophysiology of MS and protective treatments; and the education of young physicians and scientists in MS-related research, on both the translational and the basic science levels.
The Holtom-Garrett Family Professor of Neurology and a professor of neurology in the Medical School, Dr. Segal has a goal to see discoveries made in the laboratory on the development of MS translated into practical treatments. Together with a multidisciplinary team, he is seeking to develop therapeutic vaccines and novel immune-modulating agents to improve the treatment of MS and advance nervous tissue repair.
Dr. Segal received a bachelor’s degree in biochemistry in 1984 and medical degree in 1988, both from Brown University. He served an internship in internal medicine at the University of Chicago and a residency in neurology at the Weill Medical College of Cornell University. He conducted research in neuroimmunology as a clinical associate in the National Institute of Neurological Disorders and Stroke, National Institutes of Health, from 1992-93, and as a research associate in the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, from 1993-99. Throughout his NIH tenure, Dr. Segal served as a lieutenant commander in the Public Health Service.
He was on faculty at the University of Rochester as an attending neurologist, associate professor and director of neuroimmunology research prior to coming to Michigan.
Dr. Segal’s research interests are in the immunopathology of multiple sclerosis. His discoveries have contributed to the current understanding of how different types of white blood cells and the chemical messengers that they secrete perpetuate inflammation and mediate tissue injury in the central nervous system during multiple sclerosis and similar diseases. He is the inventor of two patents for immunotherapeutic agents in MS.
His scientific contributions have been recognized by numerous awards, including a Commendation Medal for Excellence from the Public Health Service, a Harry Weaver Junior Faculty Award from the National Multiple Sclerosis Society (NMSS), and the Stanley Aronson Award for Excellence in the Clinical Neurosciences.
A member of the American Association of Immunologists, the American Academy of Neurology and the American Neurological Association, Dr. Segal is an ad hoc reviewer for NIH study sections and numerous professional journals, including Cellular Immunology, Clinical Immunology and Immunopathology, Immunopharmacology, Journal of Immunology, Journal of Experimental Medicine, Neurology, and Proceedings of the National Academy of Sciences. He also serves as a permanent member on the scientific study section of the NMSS.
- Multiple Sclerosis
Medical School or Training
- Brown University, 1988
- Memorial Sloan Kettering Cancer Center, Neurology, NY, 1992